OPKO Health, Inc. Other Liabilities and Deferred Revenue, Noncurrent
OPKO Health, Inc. (OPK) had Other Liabilities and Deferred Revenue, Noncurrent of $11.39 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Notes
us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent · last filed 2026-08-28
- 2026-06-30: Other Liabilities and Deferred Revenue, Noncurrent $11.39M.
- 2026-03-31: Other Liabilities and Deferred Revenue, Noncurrent $11.38M.
- 2025-12-31: Other Liabilities and Deferred Revenue, Noncurrent $11.60M.
- 2025-09-30: Other Liabilities and Deferred Revenue, Noncurrent $11.73M.
| Period end | Other Liabilities and Deferred Revenue, Noncurrent | Other Liabilities and Deferred Revenue, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $11.39M 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $11.38M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $11.60M 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $11.73M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $11.44M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $11.46M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $11.50M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $11.99M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $12.13M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $12.17M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $12.20M 10-Q · filed 2024-11-07 | |
| 2023-09-30 | $9.91M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $9.95M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $10.04M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $10.07M 10-Q · filed 2023-11-06 | |
| 2022-09-30 | $7.42M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $7.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $7.37M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $7.36M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $14.16M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $14.80M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $16.76M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $25.33M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $26.89M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $24.27M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $23.11M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $25.22M 10-K · filed 2021-02-18 | |
| 2019-09-30 | $27.56M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $29.64M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $34.19M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $33.77M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $17.49M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $22.13M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $18.26M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $17.86M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $17.41M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $22.12M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $22.00M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $21.91M 8-K · filed 2019-01-29 | |
| 2016-09-30 | $9.53M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $14.19M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $14.05M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $13.66M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $18.74M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $3.75M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $3.37M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $1.03M 10-K · filed 2016-02-29 | $3.56M 10-K · filed 2015-02-27 |
| 2014-09-30 | $3.66M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $2.02M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $679.00K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $1.51M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $1.01M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $2.19M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $1.57M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $380.00K 10-K · filed 2014-03-03 | |
| 2012-09-30 | $453.00K 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $451.00K 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $578.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |